Heptares Therapeutics

Contact
heptares.com
+442089067182

Heptares Therapeutics Ltd

BioPark, Broadwater Road
AL7 3AX Welwyn Garden City
United Kingdom
+442089067182
heptares.com
Contact
Profile News
Contact

About Heptares Therapeutics

Heptares Therapeutics Ltd., a clinical-stage company, creates novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a range of human diseases. It offers GPCR structure-based drug design, X-ray crystallography, surface plasmon resonance, fragment screening, NCE discovery, and antibody discovery. Heptares Therapeutics Ltd. has a strategic agreement with Pfizer Inc.; and strategic collaboration with Kymab Limited and Jitsubo Co., Ltd. The company was founded in 2007 and is based in Welwyn Garden City, United Kingdom. As of February 22, 2015, Heptares Therapeutics Ltd. operates as a subsidiary of Sosei Group Corporation.

Read more about Heptares Therapeutics
Facts about Heptares Therapeutics
  • Focus : Manufacturer
  • Industry : Pharma

News about Heptares Therapeutics

Heptares Therapeutics

09-Oct-2017 | people

Heptares founder Richard Henderson receives Nobel Prize in Chemistry 2017

Heptares Therapeutics is delighted that one of its founders, Richard Henderson (MRC Laboratory of Molecular Biology, Cambridge, UK), was awarded the Nobel ...

Read news
Heptares Therapeutics

04-Sep-2017 | business & finance

Heptares enters a research and drug discovery collaboration with Juntendo University

Heptares Therapeutics, the wholly-owned subsidiary of Sosei Group Corporation, announces the launch of a new research collaboration under its ORBIT ...

Read news
Heptares Therapeutics

28-Jun-2017 | research and development

Heptares enters a Research and Drug Discovery Collaboration with New York University

New programme focused on key GPCR target implicated in aggressive brain cancer

Read news
Heptares Therapeutics

08-Dec-2016 | science

Structure of CCR9 chemokine receptor solved

Offering opportunity to apply structure-based design across chemokine receptor family

Read news
Heptares Therapeutics

11-Aug-2015 | business & finance

Heptares and AstraZeneca enter agreement to develop treatments for a range of cancers

Heptares Therapeutics announced that it has entered into a licensing agreement with AstraZeneca under which AstraZeneca will acquire exclusive global ...

Read news
Heptares Therapeutics

31-Jul-2015 | research and development

Heptares Initiates Proprietary Therapeutic Antibody Program against a GPCR Target

MorphoSys AG announced that its partner Heptares Therapeutics, a wholly owned subsidiary of Sosei Group Corporation, has exercised an option to initiate a ...

Read news
Heptares Therapeutics

22-Jun-2015 | research and development

Heptares: Positive outcome from clinical study with first ever selective M1 agonist in Alzheimer's disease

Heptares Therapeutics announced the positive outcome of its Phase 1a study with HTL9936, the first-ever fully selective muscarinic M1 receptor agonist to ...

Read news
Heptares Therapeutics

27-Jan-2015 | science

Heptares scientists to receive Malcolm Campbell Memorial Prize

Heptares Therapeutics announced that the Malcolm Campbell Memorial Prize for 2015 has been awarded to Miles Congreve (Vice President of Chemistry), Fiona ...

Read news
Show more news about Heptares Therapeutics

Here you will find Heptares Therapeutics Ltd